Etubics Reports Breakthrough Next Generation HIV Vaccine at AIDS Conference
SEATTLE--At the AIDS Vaccine 2007 Conference today, Etubics Corporation reported on a novel adenovirus vector vaccine that can boost the HIV/AIDS virus immune response and deliver vaccination against a second disease at the same time.
For the first time ever, Etubics has demonstrated that animals can be immunized against the HIV virus using Etubics HIV-1, E2b-gag vaccine, then at a later date their immunity can be boosted by a second immunization with the same vaccine. This second immunity boost has been unable to be produced prior to this study. Furthermore, the E2b-gag vaccine was found to stimulate the most important early warning system which is composed of dendritic cells (DC), CD8+ and CD4+ T-cells. Stimulation of the DC's also stimulates natural killer T-cells that are part of the innate immune response. Together, these immune cells and possibly HIV antibodies are needed to protect against the HIV/AIDS virus infection.
"We are excited to have discovered these findings during our animal trials. The HIV vaccine development industry has been in search of a product that can be used over and over to boost the immune response following an initial vaccination and we believe that we have found such a product," stated Dr. Frank Jones, founder, Chairman and Chief Executive Officer of Etubics and leader of the scientific efforts. "We are encouraged enough that we have initiated non-human primate trials which, if successful, will move us one step closer to the clinics."
"This avant-garde E2b vector vaccine technology needs to find its way into the armamentarium of healthcare workers attempting to treat patients with HIV/AIDS but also in other areas such as influenza, including bird flu, herpes simplex virus, and the treatment of a variety of cancer patients," said Dr. Andrea Amalfitano, professor at Michigan State University and Chairman of Etubics Scientific Board as well as a patent holder and creator of Etubics technology. "Presently, I am working with Etubics to start a Phase I/II cancer trial with our E2b based cancer vaccines. I also look forward to testing the HIV E2b-gag vaccine in humans within a few years, if initial trials on primates go as expected."
Etubics breakthrough vaccine technology is based on over ten years of gene therapy studies at the University of Michigan in Ann Arbor. Etubics is also pursuing vaccines against other viruses, bacteria, and parasites, each of which are known to cause difficult to treat diseases. The Company anticipates initiating human Phase I clinical trials as soon as it gains FDA validation of its proprietary E.C7 cell line which is used to manufacture the E2b vaccines.
Since its first meeting in Paris, France, in 2000, the AIDS Vaccine Conference has emerged as the premier forum for the exchange of scientific information relating to the challenges of developing and testing an effective vaccine against HIV. More than 900 AIDS vaccine researchers from 48 countries have registered for this year's conference. Attendees will include public health and policy experts, clinicians, epidemiologists and members of the corporate sector. The conference examines a broad spectrum of issues in AIDS vaccine development. Basic science advances in HIV immunology and vaccine design will be emphasized along with performing clinical trials in emerging countries. AIDS Vaccine 2007 is organized by the Global HIV Vaccine Enterprise, an alliance designed to promote innovation and collaboration to speed the search for an HIV vaccine.
About Etubics
Etubics is a Seattle-based biopharmaceutical firm that concentrates on developing "next generation" protective and therapeutic vector vaccines that stimulate cell-mediated immunity. These "next generation" vaccines are able to be rapidly manufactured in high volumes and are designed to respond to emerging infectious diseases, such as influenza, HIV, certain bioterrorism agents and certain cancers. Etubics was established in 2005, by Dr. Frank Jones, using technology from the University of Michigan, and is currently engaged in research, development and commercialization of its proprietary and novel adenovirus vector vaccine products. For more information on Etubics, visit www.etubics.com.
Statements herein relating to future financial, business performance, conditions or strategies and other financial and business matters, including expectations regarding future revenues and operating expenses, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Etubics is a private company. Etubics cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by Etubics to secure and maintain relationships with collaborators; risks relating to the early state of Etubics's product candidates under development; uncertainties relating to clinical trials; risks relating to the commercialization, if any, of Etubics proposed candidates; dependence on the efforts of third parties; dependence on intellectual property; and risks that it may lack the financial resources and access to capital to fund its operations. Further information on the factors and risks that could affect Etubics business, financial conditions and results of operations, are contained in Etubics's documents on file at the Company. These forward-looking statements speak only as of the date of this press release and Etubics assumes no duty to update forward-looking statements.
Contacts
Richmond Public Relations
Media contacts
Kimberly Jones or Louie Richmond, 206-682-6979
kimj@richmondpr.com
or
Etubics Corporation
Dr. Frank Jones, 206-818-2857
frj@etubics.com
For the first time ever, Etubics has demonstrated that animals can be immunized against the HIV virus using Etubics HIV-1, E2b-gag vaccine, then at a later date their immunity can be boosted by a second immunization with the same vaccine. This second immunity boost has been unable to be produced prior to this study. Furthermore, the E2b-gag vaccine was found to stimulate the most important early warning system which is composed of dendritic cells (DC), CD8+ and CD4+ T-cells. Stimulation of the DC's also stimulates natural killer T-cells that are part of the innate immune response. Together, these immune cells and possibly HIV antibodies are needed to protect against the HIV/AIDS virus infection.
"We are excited to have discovered these findings during our animal trials. The HIV vaccine development industry has been in search of a product that can be used over and over to boost the immune response following an initial vaccination and we believe that we have found such a product," stated Dr. Frank Jones, founder, Chairman and Chief Executive Officer of Etubics and leader of the scientific efforts. "We are encouraged enough that we have initiated non-human primate trials which, if successful, will move us one step closer to the clinics."
"This avant-garde E2b vector vaccine technology needs to find its way into the armamentarium of healthcare workers attempting to treat patients with HIV/AIDS but also in other areas such as influenza, including bird flu, herpes simplex virus, and the treatment of a variety of cancer patients," said Dr. Andrea Amalfitano, professor at Michigan State University and Chairman of Etubics Scientific Board as well as a patent holder and creator of Etubics technology. "Presently, I am working with Etubics to start a Phase I/II cancer trial with our E2b based cancer vaccines. I also look forward to testing the HIV E2b-gag vaccine in humans within a few years, if initial trials on primates go as expected."
Etubics breakthrough vaccine technology is based on over ten years of gene therapy studies at the University of Michigan in Ann Arbor. Etubics is also pursuing vaccines against other viruses, bacteria, and parasites, each of which are known to cause difficult to treat diseases. The Company anticipates initiating human Phase I clinical trials as soon as it gains FDA validation of its proprietary E.C7 cell line which is used to manufacture the E2b vaccines.
Since its first meeting in Paris, France, in 2000, the AIDS Vaccine Conference has emerged as the premier forum for the exchange of scientific information relating to the challenges of developing and testing an effective vaccine against HIV. More than 900 AIDS vaccine researchers from 48 countries have registered for this year's conference. Attendees will include public health and policy experts, clinicians, epidemiologists and members of the corporate sector. The conference examines a broad spectrum of issues in AIDS vaccine development. Basic science advances in HIV immunology and vaccine design will be emphasized along with performing clinical trials in emerging countries. AIDS Vaccine 2007 is organized by the Global HIV Vaccine Enterprise, an alliance designed to promote innovation and collaboration to speed the search for an HIV vaccine.
About Etubics
Etubics is a Seattle-based biopharmaceutical firm that concentrates on developing "next generation" protective and therapeutic vector vaccines that stimulate cell-mediated immunity. These "next generation" vaccines are able to be rapidly manufactured in high volumes and are designed to respond to emerging infectious diseases, such as influenza, HIV, certain bioterrorism agents and certain cancers. Etubics was established in 2005, by Dr. Frank Jones, using technology from the University of Michigan, and is currently engaged in research, development and commercialization of its proprietary and novel adenovirus vector vaccine products. For more information on Etubics, visit www.etubics.com.
Statements herein relating to future financial, business performance, conditions or strategies and other financial and business matters, including expectations regarding future revenues and operating expenses, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Etubics is a private company. Etubics cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by Etubics to secure and maintain relationships with collaborators; risks relating to the early state of Etubics's product candidates under development; uncertainties relating to clinical trials; risks relating to the commercialization, if any, of Etubics proposed candidates; dependence on the efforts of third parties; dependence on intellectual property; and risks that it may lack the financial resources and access to capital to fund its operations. Further information on the factors and risks that could affect Etubics business, financial conditions and results of operations, are contained in Etubics's documents on file at the Company. These forward-looking statements speak only as of the date of this press release and Etubics assumes no duty to update forward-looking statements.
Contacts
Richmond Public Relations
Media contacts
Kimberly Jones or Louie Richmond, 206-682-6979
kimj@richmondpr.com
or
Etubics Corporation
Dr. Frank Jones, 206-818-2857
frj@etubics.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.